2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.